Selvigaltin (GB1211), an orally available small molecule galectin-three inhibitor designed like a procedure for liver fibrosis and cirrhosis, was evaluated to assess the outcome of hepatic impairment on its pharmacokinetics and safety to handle regulatory specifications. Table four Statistical evaluation of dose proportionality on the pharmacokinetic parameters of GB1211 following https://juvenaln877amx0.wikiitemization.com/user